SynOx Therapeutics
Manufacturing · Ireland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3 Dublin Landings North Wall Quay, Dubli...Website
www.synoxtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About SynOx Therapeutics
SynOx Therapeutics is a late clinical-stage biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1 related and macrophage driven disorders.Explore more
SynOx Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SynOx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if SynOx Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on SynOx Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at SynOx Therapeutics
Product Launch: Get notified when SynOx Therapeutics launches new products
Click to see if SynOx Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once SynOx Therapeutics has new funding data
Check if SynOx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
SynOx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined SynOx Therapeutics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
SynOx Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SynOx Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SynOx Therapeutics.
SynOx Therapeutics financials insights
Gather financial insights about SynOx Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$43.8M
2024
Debt
$35M
Series B
$92M
SynOx Therapeutics Tech Stack
A closer look at the technologies used by SynOx Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Project
Spending/Investment, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Funding
Funding
SynOx Therapeutics News & Media
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
Charles “Chip” Romp and Tom Heyman join SynOx’s Board, bringing deep launch, lifecycle, and corporate development expertise as the company advances its next-generation therapy emactuzumab toward key regulatory and commercial milestones Charles “Chip” Romp and Tom Heyman join SynOx’s Board, bringing deep launch, lifecycle, and corporate development expertise as the company advances its next-generation therapy emactuzumab toward key regulatory and commercial milestonesSynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline
Top-Line Results from Study Evaluating Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) Expected in First Quarter of 2026 Top-Line Results from Study Evaluating Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) Expected in First Quarter of 2026SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)
DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to emactuzumab for the treatment of TGCT patients that are not amenable to or who would not benefit from surgery. Emactuzumab, a potentially best-in-cSynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy
Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding SynOx Therapeutics
Sign Up For FreeTo access detailed company insights
SynOx Therapeutics is a late clinical-stage biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1 related and macrophage driven disorders.... Read More
